menu
    • menu

    Company profile for Caliway Biopharmaceuticals

    NEW Drugs in Dev: 1
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    PMC Isochem is your partner for smart CDMOs of Intermediates, APIs, & excipients & a catalog of Intermediates & Generic APIs.

    Virtual Booth

    Contact Supplier

    Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Founded in 2012, Caliway focuses on breakthrough medical aesthetics and inflammatory medicine discovery of small-molecule therapeutics, targeting areas with unmet medical needs and a growing market worth more than $10 billion to expand their market opportunity. Our leading candidate, CBL-514, is a first-in-class new drug that can trigger adipocyte apoptosis at the injection site and reduce subcutaneous fat effectively without ...
    Founded in 2012, Caliway focuses on breakthrough medical aesthetics and inflammatory medicine discovery of small-molecule therapeutics, targeting areas with unmet medical needs and a growing market worth more than $10 billion to expand their market opportunity. Our leading candidate, CBL-514, is a first-in-class new drug that can trigger adipocyte apoptosis at the injection site and reduce subcutaneous fat effectively without causing tissue necrosis or prominent side effects. The results of the CBL-514 clinical trial demonstrated its promising potential in competing in the fat reduction market that is worth more than USD$100 billion.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Caliway BiopharmaceuticalsTaiwan Flag
    Country
    Country
    Taiwan
    Address
    Address
    32F.-9, No.99, Sec.1, Xintai 5th Rd., Xizhi Dist., New Taipei City 221
    Telephone
    Telephone
    +886-2-2697-1355
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.caliway.com.tw/en/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/caliway/?trk=ppro_cprof
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    BPI Europe

    BPI Europe

    Not Confirmed

    envelop Contact Supplier

    BPI Europe

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Caliway’s fat drug CBL-514 phase 2 gains ASJ recognition
    Caliway’s fat drug CBL-514 phase 2 gains ASJ recognition

    13 Apr 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/caliways-fat-reduction-drug-cbl-514-phase-2-clinical-results-accepted-by-asj-cbl-0204s-demonstrated-efficacy-and-safety-gain-further-academic-recognition-302740304.html

    PR NEWSWIRE
    13 Apr 2026
    Share Share
    Caliway Unveils Multi-Mechanism Preclinical Research at TMASO
    Caliway Unveils Multi-Mechanism Preclinical Research at TMASO

    16 Dec 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/caliway-biopharmaceuticals-presents-preclinical-research-supporting-a-multi-mechanism-approach-to-weight-management-at-tmaso-2025-302643052.html

    PR NEWSWIRE
    16 Dec 2025
    Share Share
    Caliway Hits Milestones with MSCI Index, Ph 3 SUPREME-01 Approval
    Caliway Hits Milestones with MSCI Index, Ph 3 SUPREME-01 Approval

    12 Aug 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/caliway-met-dual-milestones-with-msci-global-standard-index-inclusion-and-health-canada-has-approved-the-phase-3-supreme-01-study-302527535.html

    PR NEWSWIRE
    12 Aug 2025
    Share Share
    Caliway Gets FDA Nod for CBL-514 IND Application
    Caliway Gets FDA Nod for CBL-514 IND Application

    28 Jul 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/caliway-announces-fda-clearance-of-ind-application-for-cbl-514-to-proceed-with-supreme-01-the-first-global-pivotal-phase-3-study-for-reducing-abdominal-subcutaneous-fat-302514808.html

    PR NEWSWIRE
    28 Jul 2025
    Share Share
    Caliway to Present Preclinical Data on CBL-514 at BIO 2025
    Caliway to Present Preclinical Data on CBL-514 at BIO 2025

    10 Jun 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/caliway-to-present-first-preclinical-data-on-cbl-514-for-glp-1-weight-rebound-management-at-bio-2025-302477476.html

    PR NEWSWIRE
    10 Jun 2025
    Share Share
    Caliway's EOP2 Meeting with FDA for CBL-514 in Fat Reduction
    Caliway's EOP2 Meeting with FDA for CBL-514 in Fat Reduction

    14 May 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/caliway-announces-successful-eop2-meeting-with-the-fda-for-cbl-514-in-reduction-of-abdominal-subcutaneous-fat-302454923.html

    PR NEWSWIRE
    14 May 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search